clinical trials for glp-1 obesity meds actively recruiting What is the pipeline future medications for obesity? 📣 NOW RECRUITING: New Clinical – Transforming obesity: The advancement of

Retatrutide (LY3437943): This Lilly molecule is a triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors (so called Triple G)

doi:10.1136/openhrt-2016-000469 3 Fulgoni VL 3rd, Gaine PC, Scott MO, Ricciuto L, DiFrancesco L

Using them on the same night creates high cumulative irritation potential

The peptide does not affect blood pressure, heart rate, or cardiovascular parameters in studies

Recalls & Warnings June 10, 2025 Zicam and Orajel Swabs Recalled On June 6, 2025, Church & Dwight Co., Inc

Each individual dose is smaller, potentially reducing per-dose side effects